Health Discoveries in Mesothelioma

Kidney damage is linked to well-known cancer drug

July 29, 2010
A well-known drug treating cancer patients, including those with malignant mesothelioma, appears to increase the risk of kidney damage, according to a study published in the Journal of the American Society Nephrology.

The drug Avastin (bevacizumab), when used in conjunction with chemotherapy, substantially increased the incidence of kidney disease when data from 16 studies that included more than 12,000 cancer patients were reviewed, the journal reported.

The researchers also found the drug leads to a significantly increased risk of Nephrotic Syndrome, which shows excess protein in urine and low protein in blood as well as high cholesterol, high triglycerides and edema.

Among the studies reviewed were six clinical trials in colorectal cancer, two in non-small cell lung cancer, three in breast cancer, two in pancreatic cancer, two in renal cell carcinoma and one in malignant mesothelioma. Patients with renal cell carcinoma and those who take high doses of bevacizumab appeared to have the highest level of risk.

The Division of Kidney Diseases and Hypertension at both the North Shore University Hospital and the Long Island Jewish Medical Center, the research hospitals of the North Shore-LIJ Health System, have comprehensive medical services and research programs on both diabetic and polycystic kidney disease.ADNFCR-2730-ID-19912996-ADNFCR
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Kidney damage is linked to well-known cancer drug: